ThinkEquity starts Synta Pharma at buy

ThinkEquity has initiated coverage of Synta Pharmaceuticals (NASDAQ:SNTA) with a “buy” rating and 12-month price target of $6, predicting that ganetespib, Synta’s lead Hsp90 inhibitor, will “potentially demonstrate efficacy in a subset of lung cancer and can likely generate peak sales of approximately $450 million to $500 million, if approved.” The stock closed at $3.55 [...]

Rodman starts Celsion at market outperform

Rodman & Renshaw has initiated coverage of Celsion (NASDAQ:CLSN) with a “market outperform/speculative risk” rating and a target price of $6, based on a discounted revenues and earnings per share valuation methodology. The stock closed at $2.75 on Tuesday. “With approximately $25 million in cash pro forma, and an enterprise value of $47 million, we [...]

Cormark raises QLT price target

On the heels of QLT (NASDAQ:QLTI; TSX:QLT) reaching a 52-week high of $5.45 (U.S.) on Wednesday, Cormark Securities raised its price target to $6.50 from $5.35, maintaining a “buy” rating on the stock. In a new report, analyst David Dean writes that QLT expects to report data this year from two clinical programs, which “do [...]